Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.

To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.

Start Date01 Aug 1998

Sponsor / Collaborator-

100 Clinical Results associated with Ranimustine

100 Translational Medicine associated with Ranimustine

100 Patents (Medical) associated with Ranimustine

226

Literatures (Medical) associated with Ranimustine

01 Jan 2024·Journal of Clinical and Experimental Hematopathology

Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study

Article

Author: Higashi, Morihiro ; Momose, Shuji ; Tabayashi, Takayuki ; Anan, Tomoe ; Takahashi, Yasuyuki ; Kizaki, Masahiro ; Naganuma, Ken

High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/ASCT) has been useful in relapsed or refractory classic Hodgkin lymphoma (RRcHL). Furthermore, a ranimustine, cytarabine, etoposide, and cyclophosphamide (MCVAC) conditioning regimen has been effective in diffuse large B-cell lymphoma. However, limited data are available regarding this conditioning regimen for cHL. In this study, we investigated the efficacy and toxicity of MCVAC for RRcHL. We retrospectively analyzed 10 patients with RRcHL who underwent ASCT preceded by the MCVAC conditioning regimen between January 2009 and December 2021 at our institution. A total of 10 patients (median [range] age, 36 [23-64] years), including 5 (50%) men and 5 (50%) women, were treated with the MCVAC regimen followed by ASCT. The median follow-up duration of the 10 patients was 25.0 months. The 36-month PFS and OS rates were 43.8% (95% CI, 11.9%-72.6%) and 64.0% (95% CI, 22.6%-87.5%), respectively. Two patients died because of treatment-related factors, and one patient died because of disease progression. Based on our findings, recognizing the risk factors for adverse events (AEs) associated with this treatment, MCVAC may be a valid treatment option for the management of RRcHL.

01 Jan 2024·[Rinsho ketsueki] The Japanese journal of clinical hematology

[Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].

Article

Author: Waki, Masato ; Kubota, Yoshitsugu

A 45-year-old woman was diagnosed with essential thrombocythemia (ET) in August 1987 and received treatment with alkylating agents (total administration dose, busulfan 378 mg, MCNU 700 mg) because of a history of myocardial infarction. In June 2000, anemia gradually progressed. A few blast cells were detected in the peripheral blood at that time. Since bone marrow biopsy revealed myelofibrosis, she received anabolic hormone therapy. She was admitted to our hospital for an evaluation of abdominal distension in February 2003. Swelling of a large paraaortic lymph node of 6 cm in diameter was detected by CT scan. Lymph node biopsy revealed diffuse large B-cell lymphoma. Lymphoma cells were positive for CD10, CD19, CD20 and kappa-chain. The clinical stage was I. Complete remission has been achieved for 57 months after treatment with combination chemotherapy combined with rituximab followed by local radiation therapy. Non-Hodgkin lymphoma secondary to ET is a rare event. Such cases should therefore be accumulated to evaluate the mechanism of onset and clinical characteristics of lymphoma secondary to ET.

01 Feb 2023·Asia-Pacific Journal of Clinical Oncology

Safety and efficacy of high‐dose cytarabine MEAM therapy and other treatments for auto‐peripheral blood stem cell transplantation: A retrospective comparative study

Article

Author: Hirakawa, Tsuneaki ; Kitano, Tomoaki ; Marumo, Atsushi ; Honma, Shunsuke ; Omori, Ikuko ; Yamaguchi, Hiroki ; Sakaguchi, Masahiro ; Nagata, Yasunobu ; Inai, Kazuki ; Takeyoshi, Atsushi ; Kaito, Yuta ; Wakita, Satoshi ; Kinoshita, Ryosuke ; Sunakawa, Mika ; Okamoto, Muneo ; Yui, Shunsuke ; Yasuda, Shunichi ; Inokuchi, Koiti ; Tokura, Taichiro ; Kuribayashi, Yasuko ; Fujiwara, Yusuke ; Asayama, Toshio ; Nakayama, Kazutaka ; Yamanaka, Satoshi ; Arai, Kunihito ; Onai, Daishi

AbstractAimThe MEAM regimen consisting of ranimustine (MCNU), etoposide (ETP), cytarabine (Ara‐C), and melphalan (MEL) is widely used before auto‐peripheral blood stem cell transplantation (auto‐PBSCT) for malignant lymphoma in Japan. The MEAM regimen generally consists of 200–400 mg/m2 for 4 days, but we decided to increase the dosage of Ara‐C from the standard to 2 g/m2 for 2 days with the aim of increasing drug transferability to the central nervous system. We evaluate the safety and therapeutic efficacy of high‐dose Ara‐C MEAM therapy.MethodsThe high‐dose Ara‐C MEAM protocol consisted of MCNU 300 mg/m2 on day –7, ETP 200 mg/m2 on days –6, –5, –4, –3 and Ara‐C 2 g/m2 on day –4 –3, and MEL 140 mg/m2 on day –2. We retrospectively analyzed 37 cases of malignant lymphoma at our institution between May 2014 and July 2020.ResultsAll patients got engraftment and there were no cases of treatment‐related mortality. In all cases, the 3‐year overall survival (OS) and progression‐free survival (PFS) after transplantation were 80.6% and 65.7%, respectively. Twenty‐one cases of diffuse large B‐cell lymphoma recurrence, for which there is proven usefulness of auto‐PBSCT, showed good results after transplantation, with the 3‐year OS and PFS after transplantation being 100% and 74.3%, respectively.ConclusionThe safety and efficacy of high‐dose Ara‐C MEAM therapy were demonstrated, but the expected therapeutic effect on central nervous system lesions could not be fully evaluated owing to the small number of cases.

100 Deals associated with Ranimustine

External Link

KEGG	Wiki	ATC	Drug Bank
D01760	Ranimustine	L01AD07	DB13832

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Myeloid Leukemia	JP	Nipro ES Pharma KK	12 Jan 1987
Esophageal Carcinoma	JP	Nipro ES Pharma KK	12 Jan 1987
Lung Cancer	JP	Nipro ES Pharma KK	12 Jan 1987
Lymphoma	JP	Nipro ES Pharma KK	12 Jan 1987

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis